Introduction
The median age of first intercourse in the United States, Western Europe, Eastern Europe (Ukraine), Eurasia (Russia), and other parts in the world is 16 years of age, with many youth having multiple sexual partners. Clinicians caring for adolescents should ask about possible coital behavior and provide effective contraception to those youth continuing to be sexually active without intent of becoming pregnant (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23) . The following box lists questions helpful to ask when discussing contraception with adolescents -particularly if they are sexually active.
A number of effective and safe contraceptive methods (see ~Tab. 19.1) are available for the sexually active adolescent who wishes to avoid pregnancy. The most effective methods of contraception include abstinence, combined oral contraceptives (24) , transdermal contraceptive patch (Ortho Evra®), vaginal contraceptive rings Coitus interruptus (NuvaRing®), progestin-releasing implant (lmplanon®), IUDs, and intramuscular depo-med roxy-progesterone acetate (Depo-Provera, DMPA); these methods have pregnancy rates under 1/100 woman-years of use (see ~Tab. 19 .2) . Unfortunately, the difference in contraceptive effectiveness between perfect use and typical use leads to millions of unintended pregnancies each year. Perfect use is defined as correct, consistent, and continued use of a method chosen by the sexually active patient. The less patient-dependent a method, the closer th e typical usage is to the perfect usage. Thus, methods such as the implant, DMPA, and IUDs have typical usage that is virtually equal to perfect usage, and the intravaginal ring and transdermal patch have better typical usage than oral contraceptive pills (OCPs). The barrier methods (condoms, diaphragms, cervical caps, vaginal sponges, female condoms, and vaginal spermicides) are not typically recommended as the only method for adolescents, unl ess they are mature and motivated enough to use them; even then, pregnancy rates are higher than with the methods ide ntified above as the most effective ones. Over the past 20 years, a number of newer contraceptive methods have bee n approved in the United States by the U.S. Federal Drug Administration; these include ECs (Preven®, Plan B®), Depo-Provera®, the ce rvical cap, Lun e lle® (injectable contraceptive with estrogen), Mire na® (an IUD with levonorgestrel), the contraceptive patch (Ortho Evra®), and an intravaginal ring(NuvaRing®) . Over the past 15 years, research has developed various ways of contraceptive steroid release (see the following box, "Methods to Deliver Steroids"), producing a number of potential advantages (see the following box, "Advantages of Newer Contraceptive Methods") . After OCPs were developed in the 1960s, the emp hasis has been on having pill formulations that have reduced estrogen and progestin dosages along with the deve lopment of phasic and exte nded dosing regimens as well as the above-mentioned newer methods. This chapter reviews some of these importa nt methods of contraception . .,. Fig. 19.1 
Oral contraceptives (OCPs; combined oral contraceptives [COCs])
One of the main contraceptives for several decades has been the COC, containing synthetic estrogen (usually ethinyl estradiol [EEL occasionally mestranol) and synthetic progesterone (several types, see the following box) (1, 2, 3, 4, 5, 6, 7) .
The mechanisms of the combined birth control pill (OCPs or COCs) include pregnancy prevention by inhibition of ovulation, cervical mucus thickening, endometrial atrophy, and tubal transport changes. When discussing OCPs with adolescents, it is helpful to note the many benefits and uses of these pills, as listed in the following box. OCPs are usually available as 28-day packs, which contain 21 days of active pills containing consistent steroid dosages (monophasic) and placebo pills for the last 7 days to allow the adolescent to continue with one pill a day. Variations on this are being developed, such as having only 2 days of placebo for each 28-day cycle or extended cycles.
Multiphasic pills have also been developed that contain steroid dosages that vary · through the month (bi-or triphasic). There is no evidence that multiphasic pills provide any benefit over monophasic formulations and are often more expensive. There is also no evidence that one OCP brand is better than another, only that an individual adolescent may prefer or tolerate one brand over another. Generally, a pill with between 20 meg and 35 meg of EE is selected. While efficacy appears to be the same, pills containing 20 meg or less of EE have been shown to have a greater rate of irregular bleeding than higher dose pills.
Some females benefit from extending the menstrual cycle to reduce the number of yea rly menstrual periods. This can be applied to those having problems worsened by their menstrual periods, such as some with epilepsy, headaches, menorrhagia, premenstrual tension syndrome (PTS), iron deficiency anemia, endometriosis, coagulation disorders; those receiving anticoagulation; athletes wishing to avoid a cycle during an important sports event; and others. Some 91-day packs are currently commercially available (Seasonique®, Seasonale®, LoSeasonique®).
OCPs may be initiated according to three different schedules. First, for the Quick Start, the patient should take the first pill immediately, and backup contraception should be used for 7 days (24) . Urine pregnancy test may be performed if patient has had unprotected sex since last menses and should be repeated if next menses is missed or there are other concerns for pregnancy. Emergency contraception may be considered if unprotected sex has occurred in the last 5 days. Quick Start may improve compli ance, decrease confusion, and provide immediate contraception. OCPs can also be started on the first day of the next menses, and no backup method is needed. Lastly, they may be started on the Sunday after the next menses. This may cause confusion, difficulty with w eekend refills, and delay in initiation, especi ally in women with irregular menses. ~Tab. 19.3 provides instruction on management of missed pills. The sexually active adol escent should be instructed th at OCPs (COCs) do not prevent STDs, and thus, condoms, are also recommended . • Headaches (severe and if they start after beginning OCPs)
• Hypertension at 140-159/1 00-1 09 mm Hg
• Major surgery without prolonged immobilization
• Migraine headaches without focal neurologic involvement.
• • Complicated structural heart disease (with pulmonary hypertension, atrial fibrillation, or history of subacute bacterial endocarditis)
• Coronary (or ischemic) heart disease (active or history)
• Deep vein thrombosis or pulmonary embolism (active of history)
• Diabetes mellitus (complicated with retinopathy, neuropathy, nephropathy)
• Headaches (including migraine headaches) with focal neurologic symptoms
• Hypertension (severe: 160+/11 0+ mm Hg or with vascular complications)
• Lactation under 6 weeks
• Liver disease (including liver cancer, benign hepatic adenoma, active viral hepatitis, severe cirrhosis)
• Pregnancy, complicated 
Cardiovascular risks and OCPs
If the adolescent has had a venous thrombosis (VT) in the past, OCPs are contraindicated (25) (26) (27) . VT risks are greater in the adolescent and young adult female than risks for arterial thrombosis. Morbid obesity is a well-known risk factor for VT, though the amount of increased risk in the otherwise healthy adolescent is not known. Most adolescents who develop a VT do not have identifiable risk factors. Screening questions for adolescents seeking OCPs in regards to VT are listed in the following box.
The following box lists risk factors for thrombosis. Death from cardiovascular disease (arterial and venous) can occur among 20-to 24-year-old females at 2-6 per million per year. Thus, death from the OCP is a small, but known risk, though the risk of death from pregnancy is much greater (1 0,25). The OCP should be stopped if the adolescent has a condition requiring prolonged bed rest, as with major surgery. Smoking should be discouraged in the adolescent but is not a reason by itself to avoid OCPs. Blood pressure can increase in those on OCPs and should be monitored. If there is a personal or family history for increased lipids, the OCP is permitted if the low density lipoprotein range is under 160 mg/dl or the triglycerides under 250. Other guidelines may be used by the clinician if these guidelines are not accepted in one's region.
OCPs and miscellaneous risks
The re are a number of so-called "minor" adve rse effects that are well-known with the OCPs, such as headaches, mood c hanges, nausea, and breast tenderness. These effects are usually tol erated and do disappea r with cessation of the pill. Though ofte n linked to OCPs, there is no clear eviden ce that weight ga in is the directly ca used by OCP/COC use. Uterine breakthrough bleeding ca n be seen with OCPs and is a common cause for stopping the O CPs. Breakthrough bleeding usu a lly resolves with continued use ofthe same OCP. O ccas ionally, a change to anothe r brand is necessary. If the brea kthro ugh bl eeding is significant, the patient should be eva luated for other causes.
Adolescents with well-contro ll ed diabetes me llitus usually do well with low dose OCPs; OCPs are not provided if complications arise, such as hype rtension, retinopathy, nephropathy, or neuropathy. Some clinicians recommend that OCPs be avoided in those with migrai ne headac hes hav ing auras and in those with worsening headaches on the OCP. Some anticonvulsants lead to reduced OCP effi cacy. These include barbiturates, phenytoin, carbamazepine, fe lbamate, topiramate, and vigabatrin. A number of other medications ca n interfere with OCP efficacy, such as rifa mpin, griseofu lvin, ketoconazole, itraco nazole, and others. Antacids a nd OCPs should be separated by at least 3 hours . Those with active live r disease should avoid OCPs.
Transdermal hormonal contraception
The use of the patch to provide contraception has become a popula r method for many adolescents and is based on decades-l ong research in using in transdermal mechanisms to de liver medication. Patients should be advised that the same adverse effects as OCPs apply, with the poss ible addition of increased breast symptoms and local dermatitis at the patch site. The contraceptive patc h is about the size of a matchbook and placed on the skin in various sites: upper outer arm, buttocks, upper torso, and abdomen . It is not placed on the breasts or skin that is irritated or cut. The patch produces a daily release of 20 meg EE and 150 meg of no re lgestromin, a ho rmone that is the active metabolite of norgesti mate. The patc h is typically started on the first menstrual day, replaced weekly for 3 wee ks, and then no patch is placed on week 4, allowing menses to occur. A Quick Start, as discussed above, may also be used for initiation . A differe nt site is chosen with each patc h application.
Pregnancy rates a re similar to the OCPs, 0.7 to 1.24 per 100 woman-years with the patch versus 2.1 8 for OCPs (1 0). This rate is not affected by exposure to water baths or saunas, strenuous exercise, or warm, humid climates. Increased risks for pregnancy include wearing a patch for more than 7 days, patch detachment, and not placing a patch after being off for 7 days. If the patch detaches, it should be reattac hed immediately . If the patch cannot be reattac hed with its own adhesive, a new patc h should be placed, and the patient should pl ace the next patch on schedule . If the patc h is off for more than 24 hours or the patie nt is more than 2 days late in c hanging it, a backup contraceptive method should be used for 7 days . Some concern has been raised that pregna ncy risks may be increased in fe ma les over 90 kg. COC efficacy is reduced in obese females but is bette r than noted with use of barrier methods a lone. This red uced efficacy is due to inc reased basal metabolic rates, a ugmented adipose tissue sequestration, a nd increased hepatic metabolism of enzym es found in obesity. 
NuvaRing vaginal ring
NuvaRing is a flexible, transparent, soft vaginal ring made of an ethylene vinyl acetate copolymer with two steroid reservoir cores providing a daily release of 15 mg EE and 120 meg of etonogestrel (desogestrel metabolite). It is placed in the vagina by the adolescent for 3 weeks and then removed for 1 week. Quick Start is possible. If the ring is expelled, it is simply cleaned and pl aced back in the vagina; if the ring is removed for more than 3 hours, a backup method of contraception is needed until the ring is back in the vagina for 7 days. It is an excellent method of contraception for those who are comfortable with their bodies. Adolescents are often reticent to use the ring due to the method of insertion and removal. Insertion can be simplified by placing the NuvaRing in an empty tampon applicator and using the applicator to insert the ring. Th e user needs to be counseled that the ring does not prevent STDs . Advantages of the ring include excellent contraceptive efficacy, easily placed as well as removed, confidential method, continuous hormone release, and rapid return of ovulation after cessation of the method. Potential adverse effects include vaginitis, vaginal discomfort, foreign body sensation, as well as th e common side effects of all COCs as mentioned above.
POPs
POPs provide contraception by cervical mucus thickening and endometrial atrophy; ovulation is not reliably inhibited, leading to pregnancy rates of 1-3 or more per 100,000. Progestins used in POPs include 0.35 mg of norethindrone (Micronor®; Nor-Q.D®) and 0.075 mg of norgestrel (Ovrette®). POPs are suggested by some clinicians for sexually active females with contraindication to estrogen (such as hypertension or coronary hea rt disease). Typical adverse effects of POPs include amenorrhea and irregular uterine bleeding. POPs should not be used by females with ectopic pregnancy history or taking certain medications, such as anticonvulsants, rifampin, and griseofulvin. POPs are not typically recommended for adolescents due to the above increased pregnancy risk and the need for an active pill (no placebos) to be taken at the same time daily, making compliance difficult for teens.
ECs
The following box lists some of the ECs that have been available (28) . The Yuzpe regimen uses combination of EE (1 00 meg) and a progestin and results in significant nausea due to the high dose of estrogen (use of antiemetic is recommended), while Pia~ B C(). ntains levonorgestrel only and thus produces less nausea and has been showtob~~(). n1e what more effective than the Yuzpe regimen. The expected pregnancy rate from one unprotected coital episode is about 8 percent; this is reduced to less than 1 percent with some ECs if used within 24 hours of unprotected sex. EC is most effective if used within the first 72 hours after unprotected sex or contraception failure but may be taken up to 5 days after coitus. If the patient is pregnant while taking ECs, the fetus is not harmed. ECs are over-the-counter in many parts of the world. They should not be used as regul ar contraception. Reasons to use ECs include having sex without. protection, slippage, or breaking of a condom; missing two or more OCPs in a row; barrier contraceptive dislodgement (such as a diaphragm or cervical cap); IUD dislodgement; and being more than 14 weeks from the last Depo-Provera® inj ection.
Injectable contraceptives
DMPA (Depo-Provera ®) is a commonly used inj ectable contraceptive th at inhibits ovul ation, thins the endometrium, and thickens the cervical mucus. It is most commonly used in the intramuscular formulation, but a subcutaneous version has been developed which may show promise for self-administration in the future. It is a reliable contraceptive if taken on a regular basis at a dose of 150 mg every 12 week.
A very low pregn ancy rate is noted at 0.3 percent. It does not co ntain estrogen and thus can be used for those with co ntraindicati ons to using estrogen. Bone loss is noted in adolescents on this co ntraceptive -an average of 3.1-5 perce nt after 2 yea rs of use. H owever, seve ral studies have shown significant bone mineral density recovery after cessation of DMPA, though it is unclea r yet whether DMPA decreases peak bone density when used during adolescents. Therefore, DMPA should be used wi th ca ution in youth at risk for low bone density, such as those with chronic renal disease, anorexia nervosa, and those with limited mobility (29) . Use of Depo-Provera often leads to irregul ar menstrual periods and then amenorrhea. The following box provides a partial list of adverse effects. Benefits of this contraceptive include reli ab le contraception, reduced dysmenorrhea, less seizure activity in some females with epilepsy, and lower PTS.
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Other injectable contraceptives that are available are Lunelle® (United States), Cyclo-Provera, and Cyclofem (5 mg estradiol cypionate and 25 mg medroxyprogesterone acetate [MPNE2C]); these combination injectables (containing estrogen and progesterone) are given intramuscularly every month (every 28-30 days) and have very high contraceptive efficacy. Since it contains estrogen, dysfunctional uterine bleeding and amenorrhea are not as common as noted with Depo-Provera. Another injectable product is Mesigyna® (with 50 mg of norethindrone and 5 mg of estradiol valerate).
The etonogestrel-releasing implant (available as lmplanon® in the United States since 2006) is a subdermal implant consisting of one 40 mm long, 2 mm diameter rod. This rod is made up of a core containing 68 mg of etonogestrel within a rod of ethylene vinyl acetate copolymer covered in a memberane of the same material. This implant is inserted subdermally, typically in the region of the bicipital groove, using the sterile preloaded inserter. lmplanon provides 3 years of contraception by releasing a steady dose of progestin causing inhibition of ovulation and increasing cervical mucus viscosity. As a progestin-only method of contraception, the implant does not have the side effects or contra indications associated with estrogen containing methods. Unlike MPA, the implant does not cause decreased levels of estrogen and thus does not decrease bone density.
The benefits include high efficacy, long-acting, non-estrogen-containing, cost effective, requires little effort of the part of the patient, rapid return to fertility, and the benefits of other progestin-only methods. Adverse affects include irregular bleeding, headaches, acne, weight gain, possible mood disturbance, and increased blood pressure. If irregular bleeding occurs, the patient should be evaluated for other causes. If no other cause is found and the bleeding is significant or disruptive for the patient, nonsteroidal anti-inflammatory drugs, COCs (varying regimens), or EE have been shown to be effective to treat breakthrough bleeding due to the implant and possibly other progestin-only methods as well.
The effect of lmplanon may be decreased in those with I iver disease and by medications that induce CYP3A, such as many antiepileptics, rifampin, and Saint-John's-wort. Like DMPA, many women eventually experience amenorrhea with the implant. Barriers to use include cost and the need for insertion and removal. The need for removal by a trained professional may also be seen as a benefit in the adolescent population as this gives the practitioner an opportunity to counsel the patient on family planning, safer sex practices, and additional contraception options as well as to conduct appropriate screening prior to the adolescent discontinuing this method, which may decrease unintended pregnancy. Overall, implantable contraception is an excellent option for teens.
IUD
A number of IUDs are available in the world; the three types avail able in the United States are Progestasert IUD®, the ParaGard® (Copper T380A), and the Mirena® IUD. The following box lists the contraceptive mech anisms of IUDs.
Progestasert IUD® is replaced annually and has an expulsion rate of 2.7 percent, while ParaGard® is repl aced every 8 to 10 years and has an expulsion rate of 5 percent. In the United States, concern has been raised about a possible link between its use and PID in females due to often criticized research dating to the 1980s. Though controversial, it has limited the use of IUDs in adol escents in the United States; it is used by 12 percent of contraceptive-using women throughout the world. Data on the currently available IUDs show no increase in risk of PID unless the patient has an infection with Chlamydia or gonorrhea at the time of placement. Therefore, patients should be screened for sexually transmitted infections (STis) prior to IUD placement.
Mirena IUD (Levonorgestrel-containing IUD; LNG-IUD) is a second-generation of steroid-releasing IUDs. It releases 20 meg of levonorgestrel per 24 hours over the first 5 years of use, decreasing to 10 meg per day after 5 years. It is a popular IUD used by more than 2 million women in the world. It has a failure rate of 0.2 percent in the first year and 0.7 percent at 5 years. It exerts a local effect on the endometrium as well as the cervical mucus; ovulation may continue, and endometrial thinning can lead to amenorrhea. The foll owing box lists potential adverse effects of Mirena IUD, the most common of which is irregular bleeding. It has been used to redu ced menstrual bleeding in females with dysfunctional uterine ble-eding because it can reduced menstrual bl ood loss by 90 percent. Contraindications to Mirena IUD use include distorted uterine cavity, history of subacute bacterial endocarditis, prostheti c heart valves, and active PID.
Barrier methods
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ParaGard® (Copper T380A) is a copper T IUD which prevents pregnancy by the interference of sperm motility by the copper ions. ParaGard® is highly effective with a first year failure rate of 0.8 percent with typical usage and a high rate of continuation among adolescents. The primary benefit to ParaGard® is that it is nonhormonal and can therefore be used as reliable contraception in those with contraindi cations to hormone use or history of side effects with hormonal contraception or those patients wishing to avoid hormone usage for other reasons. Adverse effects are primarily increased dysmenorrhea and menstrual bleeding, abdominal pain, expulsion, and rarely perforation . Contraindications are similar to those for Mirena. In general, IUDs are a safe, effective, long-term method of birth control that can be used in nulliparous adolescents. Whil e not recommended for teens at high risk for STis, IUDs have not been found to increase r,isk of PID, nor have they been found to affect future fertility.
Barrier methods
Diaphragm and vaginal spermicides
The following box, "Vaginal Barrier Contraceptives/' lists barrier contraceptives. These methods are only recommended for highly motivated sexually active individuals. Clinicians can lea rn to fit diaphragms, helping determine the proper size, and teaching the youth successful use of this method. The diaphragm is used with vaginal cream or foam and is often used with the condom. Vaginal contraceptives or spermicides include foams, j ellies, creams, suppositories, and a contraceptive film. Contraindications to diaphragm use are listed in the following box, "Contraindications to Use of the Diaphragm," and advantages of vaginal contraceptives are listed in th e box, "Vaginal Contraceptive Advantages." Side effects include vaginal odor and, in rare cases, allergic reactions. Females who have diabetes mellitus and use a diaphragm have increased risks for urinary tract infections. In rare cases, toxic shock syndrome may occur, and the diaphragm is contraindicated in a female having a history of toxic shock syndrom e.
Cervical cap
The Prentif® cavity-rim cervica l cap is a small, latex cap (with spermicide placed inside) that is half the size of a diaphragm and fits around the cervix via suction. Four cervi ca l sizes are avail able and about one-fourth of females cannot be f itted with a cervical cap. The clinician should obtain cervical cytology before and at the time of cervical cap fitting because cervical dysplasia has been reported in cap users; additional cervi ca l cytology is also recommended 3 months after the fitting. Contraindications to cap use include cervical laceration, cervical scarring, and a history of toxic shock syndrom e. 
Vaginal contraceptive sponge
The sponge is made of polyurethane with a concave shape; it is a disposable method available without prescription, inserted in the vagina up to 2 days before sex and left in place 6 to 24 hours after coitus. Adverse effects include vulvar rash, vaginal odor, pruritus, candidiasis, and increased risk for urinary tract infection as well as toxic shock syndrome. Its contraceptive efficacy is similar to other barrier contraceptives.
Female condom
The female condom is a polyurethane bag or sheath that does not require a prescription. It is placed in the vagina prior to coitus; it is not used with a male condom. Some STD protection is provided by the female condom, and its overall contraceptive efficacy is similar to that of other barrier contraceptives-acceptable, but not as good as oral contraceptives.
Male condom
Male condoms are recommended to reduce the risk for STDs as well as pregnancy. Their contraceptive efficacy is similar to other barrier methods. They must be used correctly with each act of coitus or their efficacy becomes considerably reduced. Latex condoms are associated with increased breakage rates when exposed to high temperatures and/or ultraviolet light; they are also weakened by exposure to oilbased lubricants. Latex allergy is noted in 7 percent of the general population, and the polyurethane condom can then be used. In general, male condom usage should be encouraged in the adolescent population primarily for STI prevention. However, barrier methods are typically not recommended as the sole method of birth control in adolescents.
Summary
Contraception is an important concept for sexually active youth who wish to avoid unwanted, unplanned pregnancy. This chapter has reviewed effective methods of contraption that are available. Clinicians caring for adolescents should ask about the sexual behavior of these youth and provide advice on contraception, beginning with abstinence. Sexual responsibility involves prevention of unwanted pregnancy, premature childbearing, and STis. A summary of contraceptive options for sexually active adolescent females having chronic illness is provided in ~Tab. 19.5. 
Internet sites
